Oncolytics Biotech announced two abstracts describing both pooled safety and tolerability data and the mechanism of REOLYSIN will be presented at the European Society for Medical Oncology 2017 Congress.
Oncolytics Biotech (TSX:ONC) (OTCQX:ONCYF) announced two abstracts describing both pooled safety and tolerability data and the mechanism of REOLYSIN will be presented at the European Society for Medical Oncology 2017 Congress.
As quoted in the press release:
The abstracts will be published online on the ESMO website at 3:05 ET on Wednesday, August 30. The conference is taking place from September 8-12, 2017, in Madrid, Spain.
“The pooled analysis of patients treated with intravenous pelareorep is the largest safety database available for this class of agents in combination with chemotherapy,” said Dr. Andres Gutierrez, Chief Medical Officer at Oncolytics Biotech. “While our efficacy in metastatic breast cancer announced earlier this year at AACR was captivating, the safety component of pelareorep increases the benefit-risk ratio of the therapy and supports its further development. We are particularly excited to present these results as other immuno-oncology agents in the same class have had limited or no experience with systemic administration.”
The Company also announced that it has been granted an End-of-Phase 2 meeting with the United States Food and Drug Administration (FDA), taking place in August 2017. The meeting will address registration pathways for REOLYSIN® for the treatment of metastatic breast cancer, the indication for which the FDA has granted Fast Track designation. The Company expects to announce the outcome of this meeting in the fourth quarter of 2017.